RA CAPITAL MANAGEMENT, L.P.
Q3 2025 13F Holdings
- Locationboston, MA
- Num holdings
67
- Value ($000)
$8,115,527
- Date Filed11/14/2025
- Form type13F-HR
- CIK0001346824
- All SEC filings
- NoteHoldings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q3 2025 toSelect Quarter
Issuer Name | Class | CUSIP | VALUE | % | Shares | Principal | Option Type |
|---|---|---|---|---|---|---|---|
ASND ASCENDIS PHARMA A/S - ADR | SH | 04351P101 | $2.04 B | 25 % | 10,281,496 | ||
RYTM RHYTHM PHARMACEUTICALS INC | SH | 76243J105 | $573.76 M | 7 % | 5,681,359 | ||
PCVX VAXCYTE INC | SH | 92243G108 | $431.01 M | 5 % | 11,965,991 | ||
RNA AVIDITY BIOSCIENCES INC | SH | 05370A108 | $376.49 M | 5 % | 8,641,031 | ||
CDTX CIDARA THERAPEUTICS INC | SH | 171757206 | $322.28 M | 4 % | 3,365,523 | ||
SIONNA THERAPEUTICS INC | SH | 829401108 | $307.20 M | 4 % | 10,445,322 | ||
ETNB 89BIO INC | SH | 282559103 | $292.38 M | 4 % | 19,889,683 | ||
NEWAMSTERDAM PHARMA CO NV | SH | N62509109 | $288.35 M | 4 % | 10,138,938 | ||
MLYS MINERALYS THERAPEUTICS INC | SH | 603170101 | $277.72 M | 3 % | 7,323,750 | ||
JANX JANUX THERAPEUTICS INC | SH | 47103J105 | $273.48 M | 3 % | 11,189,693 |
Rows Per Page
10
- 10
- 50
- 100